Therefore, this study aimed to elucidate the underlying mechanisms of acquired trastuzumab resistance in vitro and investigate the efficacy of HER2-targeted therapies in overcoming trastuzumab resistance in HER2-amplified GC cell lines. Here, ERBB2 is linked to gastric cancer.